Literature DB >> 11295419

Urinary tract infection in adults: research priorities and strategies.

A R Ronald1, L E Nicolle, E Stamm, J Krieger, J Warren, A Schaeffer, K G Naber, T M Hooton, J Johnson, S Chambers, V Andriole.   

Abstract

Waning interest in urinary tract infection (UTI) research has limited clinical advances during the past two decades. Although care has improved for some specific UTI syndromes, there is limited evidence for most of the decisions made each day in the management of these infections. Additional clinical research is necessary to improve UTI prevention and care strategies.

Entities:  

Mesh:

Year:  2001        PMID: 11295419     DOI: 10.1016/s0924-8579(01)00303-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  48 in total

1.  Vaccine Development for the Prevention of Urinary Tract Infections.

Authors:  Walter J. Hopkins; David T. Uehling
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

Review 2.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

Review 3.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

4.  Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions.

Authors:  Vasilios Kalas; Jerome S Pinkner; Thomas J Hannan; Michael E Hibbing; Karen W Dodson; Alex S Holehouse; Hao Zhang; Niraj H Tolia; Michael L Gross; Rohit V Pappu; James Janetka; Scott J Hultgren
Journal:  Sci Adv       Date:  2017-02-10       Impact factor: 14.136

Review 5.  Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

Authors:  Laurel K Mydock-McGrane; Thomas J Hannan; James W Janetka
Journal:  Expert Opin Drug Discov       Date:  2017-06-02       Impact factor: 6.098

6.  Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.

Authors:  T Guillard; E Cambau; F Chau; L Massias; C de Champs; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

7.  A survey of outpatient antibiotic prescribing for cystitis.

Authors:  Edward Velasco; Ines Noll; Werner Espelage; Antina Ziegelmann; Gérard Krause; Tim Eckmanns
Journal:  Dtsch Arztebl Int       Date:  2012-12-14       Impact factor: 5.594

8.  Persistence of uropathogenic Escherichia Coli in the bladders of female patients with sterile urine after antibiotic therapies.

Authors:  Shu-Cheng Liu; Xiao-Min Han; Ming Shi; Zi-Li Pang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

9.  Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract.

Authors:  David A Rosen; Jerome S Pinkner; Jennifer N Walker; Jennifer Stine Elam; Jennifer M Jones; Scott J Hultgren
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

10.  Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli.

Authors:  Benjamin K Billips; Sarah G Forrestal; Matthew T Rycyk; James R Johnson; David J Klumpp; Anthony J Schaeffer
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.